Researchers from F. Hoffmann-La Roche Ltd. Report New Studies and Findings in the Area of Celiac Disease (A Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Study To Investigate the Effects of a Cathepsin S Inhibitor In...).

Researchers from F. Hoffmann-La Roche Ltd. conducted a study on the effects of a cathepsin S inhibitor on individuals with celiac disease undergoing a gluten challenge. The study did not meet its primary endpoint of increased immune response to gluten, indicating that cathepsin S inhibition may not be an effective treatment for celiac disease. The findings suggest that while the inhibitor had some beneficial effects, it did not significantly impact the immune response to gluten in participants. The study was supported by financial assistance from Hoffmann-La Roche and was published in Clinical and Translational Science. [Extracted from the article]